AI in Drug Discovery and the Life Sciences: IP and Legal Essentials Part 3
Date and Time:
Wednesday, March 18 · 4PM – 5PM CST
Location:
Campus: Mission Bay Campus
Building: Genentech Hall
Room Details: Byers Auditorium
In Person Event Details:
Artificial Intelligence is transforming drug discovery and the life sciences.
By accelerating research and expanding synthetic and analytical capabilities, AI is impacting how scientific insight is translated into products and therapies. As AI becomes increasingly embedded across discovery, development, and clinical workflows, it also introduces a diverse set of legal, regulatory, and ethical considerations that are now central to responsible innovation. Understanding these issues is critical not only for legal professionals, but also for scientists, founders, executives, investors, and institutional leaders working at the forefront of AI-enabled life sciences.
Session 3 - Protecting Innovation – AI and Intellectual Property in the Life Sciences
Speakers: Lisa Silverman, partner at Morrison Foerster; Anne Yuan, of counsel at Morrison Foerster
High level introduction to a range of issues that people working in AI in life sciences should be familiar with, including IP, privacy, cybersecurity, FDA/healthcare regulatory, ethics (e.g, bias, informed consent), and safety and product liability.